Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa F Newcomb

Showing results (11-20 of 62) with videos related to

Pageof 7
Sort By:
The Journal of Urology|November 5, 2016
Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance StudyLiam C Macleod, William J Ellis, Lisa F Newcomb, et al.
European Urology|November 5, 2020
Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology OutcomesMatthew R Cooperberg, Janet E Cowan, Karla J Lindquist, et al.
European Urology|February 14, 2018
Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance StudyJames T Kearns, Anna V Faino, Lisa F Newcomb, et al.
European Urology|March 31, 2015
Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk CalculatorDonna P Ankerst, Jing Xia, Ian M Thompson, et al.
Annals of Internal Medicine|November 29, 2017
Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance CohortsLurdes Y T Inoue, Daniel W Lin, Lisa F Newcomb, et al.
Histopathology|October 16, 2025
In reply to: 'Prostate cancer with favorable histology is not synonymous with prostate cancer indolence'Jesse K McKenney, James D Brooks, Jane K Nguyen, et al.
Cancer|October 23, 2019
Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohortsJane M Lange, Aaron A Laviana, David F Penson, et al.
The Journal of Urology|August 5, 2018
Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASSJames T Kearns, Anna V Faino, Jeanette M Schenk, et al.
JAMA Oncology|August 28, 2020
Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk StabilityMatthew R Cooperberg, Yingye Zheng, Anna V Faino, et al.
European Urology|February 14, 2018
Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance OutcomesMatthew R Cooperberg, James D Brooks, Anna V Faino, et al.
Pageof 7

Showing results (11-20 of 62) with videos related to

Sort By:
Pageof 7
The Journal of Urology|November 5, 2016
Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance StudyLiam C Macleod, William J Ellis, Lisa F Newcomb, et al.
European Urology|November 5, 2020
Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology OutcomesMatthew R Cooperberg, Janet E Cowan, Karla J Lindquist, et al.
European Urology|February 14, 2018
Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance StudyJames T Kearns, Anna V Faino, Lisa F Newcomb, et al.
European Urology|March 31, 2015
Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk CalculatorDonna P Ankerst, Jing Xia, Ian M Thompson, et al.
Annals of Internal Medicine|November 29, 2017
Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance CohortsLurdes Y T Inoue, Daniel W Lin, Lisa F Newcomb, et al.
Histopathology|October 16, 2025
In reply to: 'Prostate cancer with favorable histology is not synonymous with prostate cancer indolence'Jesse K McKenney, James D Brooks, Jane K Nguyen, et al.
Cancer|October 23, 2019
Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohortsJane M Lange, Aaron A Laviana, David F Penson, et al.
The Journal of Urology|August 5, 2018
Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASSJames T Kearns, Anna V Faino, Jeanette M Schenk, et al.
JAMA Oncology|August 28, 2020
Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk StabilityMatthew R Cooperberg, Yingye Zheng, Anna V Faino, et al.
European Urology|February 14, 2018
Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance OutcomesMatthew R Cooperberg, James D Brooks, Anna V Faino, et al.
Pageof 7